Nemes Rush Group LLC reduced its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,165 shares of the company's stock after selling 10,198 shares during the period. Nemes Rush Group LLC's holdings in Novo Nordisk A/S were worth $7,154,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Menard Financial Group LLC increased its holdings in Novo Nordisk A/S by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company's stock worth $1,463,000 after purchasing an additional 102 shares in the last quarter. Optimist Retirement Group LLC grew its holdings in Novo Nordisk A/S by 4.3% during the third quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company's stock worth $327,000 after buying an additional 112 shares in the last quarter. M. Kulyk & Associates LLC raised its position in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after buying an additional 119 shares during the last quarter. Center for Financial Planning Inc. lifted its stake in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Finally, Tradewinds Capital Management LLC boosted its holdings in Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock worth $429,000 after acquiring an additional 124 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.
Novo Nordisk A/S Stock Performance
NYSE NVO traded up $0.17 on Wednesday, hitting $68.20. 7,301,268 shares of the stock traded hands, compared to its average volume of 5,588,205. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business's fifty day moving average is $81.89 and its two-hundred day moving average is $97.68. Novo Nordisk A/S has a 12 month low of $66.58 and a 12 month high of $148.15. The firm has a market capitalization of $306.05 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 0.90 and a beta of 0.42.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.
Novo Nordisk A/S Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio (DPR) is 47.72%.
Wall Street Analyst Weigh In
NVO has been the subject of several analyst reports. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.
Check Out Our Latest Report on Novo Nordisk A/S
Novo Nordisk A/S Profile
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
See Also
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
